San Diego-based MediciNova has inked a deal for $20 million in fresh financing to back its development work. In the agreement, Aspire Capital will buy $20 million worth of MediciNova ($MNOV) shares over the next two years, allowing the biotech to set the timetable. The biotech will use the money to advance MN-221 for asthma and COPD as well as MN-166 (ibudilast), in development for the treatment of progressive MS, drug addiction and chronic pain. Release
Like what you're reading?
Click here to get more news like this delivered to your inbox everyday>>
valley fever project x the lorax lorax fisker karma super tuesday states shepard fairey
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.